Henry Chambers, MD

Professor

Dr. Chambers clinical and research interests are antimicrobial drug resistance, staphylococcal infections, experimental therapeutics, and epidemiology and pathogenesis of disease caused by Staphylococcus aureus. He is editor for the Sanford Guide to Antimicrobial Therapy and he has over 200 original publications and textbook chapters in the areas of drug resistance, endocarditis, bacterial infections, and staphylococcal diseases.

Dr. Chambers received his BA from Centre College in Kentucky and is a graduate of the Vanderbilt University School of Medicine. He trained in Internal Medicine and Infectious Diseases at the University of California San Francisco. Dr. Chambers has been a member of the medical faculty of the UCSF since 1983 where he currently is Professor of Medicine, Medical Director of Clinical Research Services for CTSI. He is an editor for Antimicrobial Agents and Chemotherapy, a reviewer for numerous medical publications, a peer reviewer for NIH study sections.

Education
B.A., - , Centre College Kentucky
Residency, - School of Medicine, University of California, San Francisco
M.D., - School of Medicine, Vanderbilt University
Publications

  1. Chambers HF, Arias CA. Rifaximin Prophylaxis and "Collateral Damage" in Patients with Advanced Liver Disease. Gastroenterology 2025. PMID: 40348034


  2. Ersoy SC, Madrigal SL, Proctor RA, Chambers HF, Xiong YQ, Bayer AS. NaHCO3 modulates the bla operon and β-lactam susceptibility in borderline oxacillin-resistant Staphylococcus aureus (BORSA). The Journal of antimicrobial chemotherapy 2024. PMID: 39704154


  3. Minter DJ, Appa A, Chambers HF, Doernberg SB. The positioning of ceftobiprole in the treatment of Staphylococcus aureus bacteremia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024. PMID: 38466317


  4. Jiang J, Komarow L, Hill C, Boutzoukas AE, Hanson B, Arias CA, Bonomo RA, Evans S, Doi Y, Satlin MJ, Weston G, Cober E, Valderrama-Beltran SL, Mendoza SS, Liu Z, Fries BC, Tambyah PA, Chambers HF, Fowler VG, van Duin D, Kreiswirth BN, Chen L. Molecular epidemiology and clinical characterization of carbapenemase-producing Enterobacter spp. from an international cohort. The Journal of infectious diseases 2024. PMID: 39667036


  5. Ersoy SC, Madrigal SL, Chen L, Mediavilla J, Kreiswirth B, Flores EA, Miller LG, Xiong YQ, Harrison EM, Blane B, Peacock SJ, Patel R, Chambers HF, Bayer AS, Proctor RA. Phenotypic and Genotypic Correlates of the NaHCO3-Responsive Phenotype Among Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates from Skin and Soft Tissue Infections (SSTIs). Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2024. PMID: 39626860


  6. Chambers HF, Fowler VG. Intertwining clonality and resistance: Staphylococcus aureus in the antibiotic era. The Journal of clinical investigation 2024. PMID: 39352382


  7. Yasmin M, Marshall SH, Chen L, Rhoads DD, Jacobs MR, Rojas LJ, Perez F, Hujer AM, Hujer KM, van Duin D, Fowler V, Chambers HF, Kreiswirth BN, Bonomo RA, Antibacterial Resistance Leadership Group. A molecular analysis of meropenem-vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae. Antimicrobial agents and chemotherapy 2024. PMID: 39162528


  8. Chambers HF, Zhang S, Evans S. Duke Infective Endocarditis Criteria 3.0 for the Clinician: Defining What Is Possible. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024. PMID: 38330224


  9. Lai L-Y, Satishkumar N, Cardozo S, Hemmadi V, Marques LB, Huang L, Filipe SR, Pinho MG, Chambers HF, Chatterjee SS. Altered PBP4 and GdpP functions synergistically mediate MRSA-like high-level, broad-spectrum β-lactam resistance in Staphylococcus aureus. mBio 2024. PMID: 38530033


  10. Wang M, Ge L, Chen L, Komarow L, Hanson B, Reyes J, Cober E, Alenazi T, Zong Z, Xie Q, Liu Z, Li L, Yu Y, Gao H, Kanj SS, Figueroa J, Herc E, Cordova E, Weston G, Ananth Tambyah P, Garcia-Diaz J, Kaye KS, Dhar S, Munita JM, Salata RA, Vilchez S, Stryjewski ME, Villegas Botero MV, Iovleva A, Evans SR, Baum K, Hill C, Kreiswirth BN, Patel R, Paterson DL, Arias CA, Bonomo RA, Chambers HF, Fowler VG, Satlin MJ, van Duin D, Doi Y, Multi-Drug Resistant Organism Network Investigators. Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024. PMID: 37738153


  11. Howard-Anderson J, Hamasaki T, Dai W, Collyar D, Rubin D, Nambiar S, Kinamon T, Leister-Tebbe H, Hill C, Geres H, Holland TL, Doernberg SB, Chambers HF, Fowler VG, Evans SR, Boucher HW. Moving beyond mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023. PMID: 37740559


  12. Ersoy SC, Proctor RA, Rose WE, Abdelhady W, Fan S-H, Madrigal SL, Elsayed AM, Chambers HF, Sobral RG, Bayer AS. Sensitizing methicillin-resistant Staphylococcus aureus (MRSA) to cefuroxime: the synergic effect of bicarbonate and the wall teichoic acid inhibitor ticlopidine. Antimicrobial agents and chemotherapy 2024. PMID: 38349162


  13. Iovleva A, McElheny CL, Fowler EL, Cober E, Herc ES, Arias CA, Hill C, Baum K, Fowler VG, Chambers HF, Greenwood-Quaintance KE, Patel R, van Duin D, Bonomo RA, Doi Y. In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals. Antimicrobial agents and chemotherapy 2024. PMID: 38289078


  14. Minter DJ, Appa A, Chambers HF, Doernberg SB. Contemporary Management of Staphylococcus aureus Bacteremia-Controversies in Clinical Practice. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023. PMID: 37950887


  15. Minter DJ, Appa A, Chambers HF, Doernberg SB. Executive Summary: State-of-The-Art Review: Contemporary Management of Staphylococcus aureus Bacteremia: Controversies in Clinical Practice. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023. PMID: 38031168


  16. Lai LY, Satishkumar N, Cardozo S, Hemmadi V, Marques LB, Huang L, Filipe SR, Pinho MG, Chambers HF, Chatterjee SS. Altered PBP4 and GdpP functions synergistically mediate MRSA-like high-level, broad-spectrum β-lactam resistance in Staphylococcus aureus. bioRxiv : the preprint server for biology 2023. PMID: 37961375


  17. Raphael E, Inamdar PP, Belmont C, Shariff-Marco S, Huang AJ, Chambers HF. Spatial clusters of extended-spectrum beta-lactamase-producing Escherichia coli causing community-onset bacteriuria due to repeat infections: cluster analysis from a large urban medical center, San Francisco, 2014-2020. Antimicrobial resistance and infection control 2023. PMID: 37858209


  18. Chambers HF, Cross HR, Souli M, Evans SR, Patel R, Fowler VG, Antibacterial Resistance Leadership Group. The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023. PMID: 37843121


  19. Boutzoukas AE, Komarow L, Chen L, Hanson B, Kanj SS, Liu Z, Salcedo Mendoza S, Ordoñez K, Wang M, Paterson DL, Evans S, Ge L, Giri A, Hill C, Baum K, Bonomo RA, Kreiswirth B, Patel R, Arias CA, Chambers HF, Fowler VG, van Duin D, Multi-Drug Resistant Organism Network Investigators. International Epidemiology of Carbapenemase-Producing Escherichia coli. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023. PMID: 37154071


  20. Fan SH, Proctor RA, Ersoy SC, Manna AC, Cheung AL, Götz F, Chambers HF, Bayer AS. Role of the NaHCO3 Transporter MpsABC in the NaHCO3-β-Lactam-Responsive Phenotype in Methicillin-Resistant Staphylococcus aureus. Microbiology spectrum 2023. PMID: 37102972


  21. Reyes J, Komarow L, Chen L, Ge L, Hanson BM, Cober E, Herc E, Alenazi T, Kaye KS, Garcia-Diaz J, Li L, Kanj SS, Liu Z, Oñate JM, Salata RA, Marimuthu K, Gao H, Zong Z, Valderrama-Beltrán SL, Yu Y, Tambyah P, Weston G, Salcedo S, Abbo LM, Xie Q, Ordoñez K, Wang M, Stryjewski ME, Munita JM, Paterson DL, Evans S, Hill C, Baum K, Bonomo RA, Kreiswirth BN, Villegas MV, Patel R, Arias CA, Chambers HF, Fowler VG, Doi Y, van Duin D, Satlin MJ, Antibacterial Resistance Leadership Group and Multi-Drug Resistant Organism Network Investigators. Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study. The Lancet. Microbe 2023. PMID: 36774938


  22. Howard-Anderson J, Hamasaki T, Dai W, Collyar D, Rubin D, Nambiar S, Kinamon T, Hill C, Gelone SP, Mariano D, Baba T, Holland TL, Doernberg SB, Chambers HF, Fowler VG, Evans SR, Boucher HW. Improving Traditional Registrational Trial Endpoints: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Complicated Urinary Tract Infection Clinical Trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022. PMID: 36031403


  23. Alexander JAN, Worrall LJ, Hu J, Vuckovic M, Satishkumar N, Poon R, Sobhanifar S, Rosell FI, Jenkins J, Chiang D, Mosimann WA, Chambers HF, Paetzel M, Chatterjee SS, Strynadka NCJ. Structural basis of broad-spectrum �-lactam resistance in Staphylococcus aureus. Nature 2023. PMID: 36599987


  24. Lodise TP, O'Donnell JN, Balevic S, Liu X, Gu K, George J, Raja S, Guptill JT, Zaharoff S, Schwager N, Fowler VG, Wall A, Wiegand K, Chambers HF, Antibacterial Resistance Leadership Group. Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults. Antimicrobial agents and chemotherapy 2022. PMID: 36394326


  25. Lodise TP, O'Donnell JN, Raja S, Guptill JT, Zaharoff S, Schwager N, Fowler VG, Beresnev T, Wall A, Wiegand K, Serti Chrisos E, Balevic S, Chambers HF, Antibacterial Resistance Leadership Group. Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers. Antimicrobial agents and chemotherapy 2022. PMID: 36394316


  26. Ersoy SC, Gon?alves B, Cavaco G, Manna AC, Sobral RG, Nast CC, Proctor RA, Chambers HF, Cheung A, Bayer AS. Influence of Sodium Bicarbonate on Wall Teichoic Acid Synthesis and �-Lactam Sensitization in NaHCO3-Responsive and Nonresponsive Methicillin-Resistant Staphylococcus aureus. Microbiology spectrum 2022. PMID: 36377886


  27. Tamma PD, Komarow L, Ge L, Garcia-Diaz J, Herc ES, Doi Y, Arias CA, Albin O, Saade E, Miller LG, Jacob JT, Satlin MJ, Krsak M, Huskins WC, Dhar S, Shelburne SA, Hill C, Baum KR, Bhojani M, Greenwood-Quaintance KE, Schmidt-Malan SM, Patel R, Evans SR, Chambers HF, Fowler VG, van Duin D, Antibacterial Resistance Leadership Group. Clinical Impact of Ceftriaxone Resistance in Escherichia coli Bloodstream Infections: A Multicenter Prospective Cohort Study. Open forum infectious diseases 2022. PMID: 36381622


  28. Chambers HF, Fowler VG, Antibacterial Resistance Leadership Group. Confronting antimicrobial resistance together. American journal of physiology. Lung cellular and molecular physiology 2022. PMID: 36193938


  29. Ersoy SC, Manna AC, Proctor RA, Chambers HF, Harrison EM, Bayer AS, Cheung A. The NaHCO3-Responsive Phenotype in Methicillin-Resistant Staphylococcus aureus (MRSA) Is Influenced by mecA Genotype. 2022. PMID: 35575577


  30. Howard-Anderson J, Dai W, Yahav D, Hamasaki T, Turjeman A, Koppel F, Franceschini E, Hill C, Sund Z, Chambers HF, Fowler VG, Boucher HW, Evans SR, Paul M, Holland TL, Doernberg SB. A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection. 2022. PMID: 35615299


  31. Shropshire WC, Dinh AQ, Earley M, Komarow L, Panesso D, Rydell K, Gómez-Villegas SI, Miao H, Hill C, Chen L, Patel R, Fries BC, Abbo L, Cober E, Revolinski S, Luterbach CL, Chambers H, Fowler VG, Bonomo RA, Shelburne SA, Kreiswirth BN, van Duin D, Hanson BM, Arias CA. Accessory Genomes Drive Independent Spread of Carbapenem-Resistant Klebsiella pneumoniae Clonal Groups 258 and 307 in Houston, TX. mBio 2022. PMID: 35357213


  32. Appa A, Adamo M, Le S, Davis J, Winston L, Doernberg SB, Chambers H, Martin M, Hills NK, Coffin PO, Jain V. Comparative one-year outcomes of invasive Staphylococcus aureus infections among persons with and without drug use: an observational cohort study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021. PMID: 33904900


  33. Lodise TP, Scheetz M, Carreno JJ, Chambers H, Fowler V, Holland TL. Associations Between Vancomycin Exposure and Acute Kidney Injury Within the Recommended Area Under the Curve Therapeutic Exposure Range Among Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. 2022. PMID: 35079599


  34. Poon R, Basuino L, Satishkumar N, Chatterjee A, Mukkayyan N, Buggeln E, Huang L, Nair V, Argudín MA, Datta SK, Chambers HF, Chatterjee SS. Loss of GdpP function in Staphylococcus aureus leads to β-lactam tolerance and enhanced evolution of β-lactam resistance. 2021. PMID: 34843389


  35. Wang M, Earley M, Chen L, Hanson BM, Yu Y, Liu Z, Salcedo S, Cober E, Li L, Kanj SS, Gao H, Munita JM, Ordoñez K, Weston G, Satlin MJ, Valderrama-Beltrán SL, Marimuthu K, Stryjewski ME, Komarow L, Luterbach C, Marshall SH, Rudin SD, Manca C, Paterson DL, Reyes J, Villegas MV, Evans S, Hill C, Arias R, Baum K, Fries BC, Doi Y, Patel R, Kreiswirth BN, Bonomo RA, Chambers HF, Fowler VG, Arias CA, van Duin D, Multi-Drug Resistant Organism Network Investigators. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. The Lancet. Infectious diseases 2021. PMID: 34767753


  36. Ersoy SC, Hanson BM, Proctor RA, Arias CA, Tran TT, Chambers HF, Bayer AS. Impact of Bicarbonate-β-Lactam Exposures on Methicillin-Resistant Staphylococcus aureus (MRSA) Gene Expression in Bicarbonate-β-Lactam-Responsive vs. Non-Responsive Strains. 2021. PMID: 34828256


  37. Chowdhury J, Patel R, Chambers H. Oral versus Intravenous Antibiotics for Endocarditis. 2021. PMID: 34525290


  38. Ersoy SC, Rose WE, Patel R, Proctor RA, Chambers HF, Harrison EM, Pak Y, Bayer AS. A Combined Phenotypic-Genotypic Predictive Algorithm for In Vitro Detection of Bicarbonate: β-Lactam Sensitization among Methicillin-Resistant Staphylococcus aureus (MRSA). 2021. PMID: 34572671


  39. Appa A, Adamo M, Le S, Davis J, Winston L, Doernberg SB, Chambers H, Martin M, Hills NK, Coffin P, Jain V. Patient-Directed Discharges Among Persons Who Use Drugs Hospitalized with Invasive S. aureus Infections: Opportunities for Improvement. The American journal of medicine 2021. PMID: 34508704


  40. Chambers HF, Evans SR, Patel R, Cross HR, Harris AD, Doi Y, Boucher HW, van Duin D, Tsalik EL, Holland TL, Pettigrew MM, Tamma PD, Hodges KR, Souli M, Fowler VG. Antibacterial Resistance Leadership Group 2.0: Back to Business. 2021. PMID: 33588438


  41. Raphael E, Glymour MM, Chambers HF. Trends in prevalence of extended-spectrum beta-lactamase-producing Escherichia coli isolated from patients with community- and healthcare-associated bacteriuria: results from 2014 to 2020 in an urban safety-net healthcare system. 2021. PMID: 34380549


  42. Ersoy SC, Chambers HF, Proctor RA, Rosato AE, Mishra NN, Xiong YQ, Bayer AS. Impact of Bicarbonate on PBP2a Production, Maturation, and Functionality in Methicillin-Resistant Staphylococcus aureus (MRSA). 2021. PMID: 33649115


  43. Chambers HF. Skin and Soft Tissue Infections. 2021. PMID: 33494875


  44. Spinelli MA, Glidden DV, Gennatas ED, Bielecki M, Beyrer C, Rutherford G, Chambers H, Goosby E, Gandhi M. Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity. The Lancet. Infectious diseases 2021. PMID: 33631099


  45. Chambers HF. Skin and Soft Tissue Infections in Persons Who Inject Drugs. 2020. PMID: 33303334


  46. Chambers HF. Rifabutin to the Rescue? The Journal of infectious diseases 2020. PMID: 32914842


  47. Chambers HF, Bayer AS. Native-Valve Infective Endocarditis. The New England journal of medicine 2020. PMID: 32757525


  48. Raphael E, Chambers HF. Differential Trends in Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Infections in Four Health Care Facilities in a Single Metropolitan Area: A Retrospective Analysis. Microbial drug resistance (Larchmont, N.Y.) 2020. PMID: 32589493


  49. Alexander JAN, Radaeva M, King DT, Chambers HF, Cherkasov A, Chatterjee SS, Strynadka NCJ. -Structural analysis of avibactam-mediated activation of the bla and mec divergons in methicillin-resistant Staphylococcus aureus. The Journal of biological chemistry 2020. PMID: 32518158


  50. Ersoy SC, Otmishi M, Milan VT, Li L, Pak Y, Mediavilla J, Chen L, Kreiswirth B, Chambers HF, Proctor RA, Xiong YQ, Fowler VG, Bayer AS. Scope and Predictive Genetic/Phenotypic Signatures of 'Bicarbonate [NaHCO3]-Responsiveness' and ß-Lactam Sensitization Among Methicillin-Resistant Staphylococcus aureus (MRSA). Antimicrobial agents and chemotherapy 2020. PMID: 32041719


  51. Lodise TP, Rosenkranz SL, Finnemeyer M, Evans S, Sims M, Zervos MJ, Creech CB, Patel PC, Keefer M, Riska P, Silveira FP, Scheetz M, Wunderink RG, Rodriguez M, Schrank J, Bleasdale SC, Schultz S, Barron M, Stapleton A, Wray D, Chambers H, Fowler VG, Holland TL. The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020. PMID: 31157370


  52. Adamson PC, Pandori MW, Doernberg SB, Komarow L, Sund Z, Tran TTT, Jensen D, Tsalik EL, Deal CD, Chambers HF, Fowler VG, Evans SR, Patel R, Klausner JD. Analytical evaluation of the Abbott RealTime CT/NG Assay for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in rectal and pharyngeal swabs. The Journal of molecular diagnostics : JMD 2020. PMID: 32247863


  53. van Duin D, Arias CA, Komarow L, Chen L, Hanson BM, Weston G, Cober E, Garner OB, Jacob JT, Satlin MJ, Fries BC, Garcia-Diaz J, Doi Y, Dhar S, Kaye KS, Earley M, Hujer AM, Hujer KM, Domitrovic TN, Shropshire WC, Dinh A, Manca C, Luterbach CL, Wang M, Paterson DL, Banerjee R, Patel R, Evans S, Hill C, Arias R, Chambers HF, Fowler VG, Kreiswirth BN, Bonomo RA, Multi-Drug Resistant Organism Network Investigators. Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. 2020. PMID: 32151332


  54. Rose WE, Bienvenida AM, Xiong YQ, Chambers HF, Bayer AS, Ersoy SC. Ability of Bicarbonate Supplementation to Sensitize Selected Methicillin-Resistant Staphylococcus aureus (MRSA) Strains to ß-Lactam Antibiotics in an Ex Vivo Simulated Endocardial Vegetation Model. Antimicrobial agents and chemotherapy 2019. PMID: 31844004


  55. Kalil AC, Holubar M, Deresinski S, Chambers HF. Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia? Antimicrobial agents and chemotherapy 2019. PMID: 31640977


  56. Ersoy SC, Abdelhady W, Li L, Chambers HF, Xiong YQ, Bayer AS. Bicarbonate Resensitization of Methicillin-Resistant Staphylococcus aureus to ß-Lactam Antibiotics. Antimicrobial agents and chemotherapy 2019. PMID: 31010857


  57. Doernberg SB, Tran TTT, Tong SYC, Paul M, Yahav D, Davis JS, Leibovici L, Boucher HW, Corey GR, Cosgrove SE, Chambers HF, Fowler VG, Evans SR, Holland TL. Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018. PMID: 30321315


  58. Guimaraes AO, Cao Y, Hong K, Mayba O, Peck M, Gutierrez J, Ruffin F, Carrasco-Triguero M, Dinoso JB, Clemenzi-Allen A, Koss CA, Maskarinec S, Chambers HF, Fowler VG, Baruch A, Rosenberger CM. A prognostic model of persistent bacteremia and mortality in complicated S. aureus bloodstream infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018. PMID: 30165412


  59. Chambers HF. Omadacycline - The Newest Tetracycline. The New England journal of medicine 2019. PMID: 30726683


  60. Alexander JAN, Chatterjee SS, Hamilton SM, Eltis LD, Chambers HF, Strynadka NCJ. Structural and kinetic analysis of penicillin-binding protein 4 (PBP4)-mediated antibiotic resistance in Staphylococcus aureus. The Journal of biological chemistry 2018. PMID: 30366985


  61. Doernberg SB, Abbo LM, Burdette SD, Fishman NO, Goodman EL, Kravitz GR, Leggett JE, Moehring RW, Newland JG, Robinson PA, Spivak ES, Tamma PD, Chambers HF. Essential Resources and Strategies for Antibiotic Stewardship Programs in the Acute Care Setting. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018. PMID: 29590355


  62. da Costa TM, de Oliveira CR, Chambers HF, Chatterjee SS. PBP4: A New Perspective on Staphylococcus aureus ß-Lactam Resistance. Microorganisms 2018. PMID: 29932109


  63. Basuino L, Jousselin A, Alexander JAN, Strynadka NCJ, Pinho MG, Chambers HF, Chatterjee SS. PBP4 activity and its overexpression are necessary for PBP4-mediated high-level ß-lactam resistance. The Journal of antimicrobial chemotherapy 2018. PMID: 29360990


  64. Bystritsky R, Chambers H. Cellulitis and Soft Tissue Infections. Volume 168 of Issue 3. Annals of internal medicine 2018. PMID: 29404597


  65. Daum RS, Kumar N, Chambers HF. A Trial of Antibiotics for Smaller Skin Abscesses. 2017. PMID: 29281570


  66. Bowen AC, Carapetis JR, Currie BJ, Fowler V, Chambers HF, Tong SYC. Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess. 2017. PMID: 29255730


  67. Chatterjee SS, Chen L, Gilbert A, da Costa TM, Nair V, Datta SK, Kreiswirth BN, Chambers HF. PBP4 Mediates ß-Lactam Resistance by Altered Function. Antimicrobial agents and chemotherapy 2017. PMID: 28807923


  68. Katayama Y, Azechi T, Miyazaki M, Takata T, Sekine M, Matsui H, Hanaki H, Yahara K, Sasano H, Asakura K, Takaku T, Ochiai T, Komatsu N, Chambers HF. Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 2017. PMID: 28827421


  69. Doernberg SB, Chambers HF. Antimicrobial Stewardship Approaches in the Intensive Care Unit. Infectious disease clinics of North America 2017. PMID: 28687210


  70. Daum RS, Miller LG, Immergluck L, Fritz S, Creech CB, Young D, Kumar N, Downing M, Pettibone S, Hoagland R, Eells SJ, Boyle MG, Parker TC, Chambers HF. A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. The New England journal of medicine 2017. PMID: 28657870


  71. Hamilton SM, Alexander JAN, Choo EJ, Basuino L, da Costa TM, Severin A, Chung M, Aedo S, Strynadka NCJ, Tomasz A, Chatterjee SS, Chambers HF. High-Level Resistance of Staphylococcus aureus to ß-Lactam Antibiotics Mediated by Penicillin-Binding Protein 4 (PBP4). Antimicrobial agents and chemotherapy 2017. PMID: 28373193


  72. Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA. Can Ceftazidime-Avibactam and Aztreonam Overcome ß-Lactam Resistance Conferred by Metallo-ß-Lactamases in Enterobacteriaceae? Antimicrobial agents and chemotherapy 2017. PMID: 28167541


  73. Chambers HF, Cross HR, Evans SR, Kreiswirth BN, Fowler VG. The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2017. PMID: 28350896


  74. Nigo M, Diaz L, Carvajal LP, Tran TT, Rios R, Panesso D, Garavito JD, Miller WR, Wanger A, Weinstock G, Munita JM, Arias CA, Chambers HF. Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis. Antimicrobial agents and chemotherapy 2017. PMID: 28232309


  75. Choo EJ, Chambers HF. Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Infection & chemotherapy 2016. PMID: 28032484


  76. Diep BA, Le VT, Badiou C, Le HN, Pinheiro MG, Duong AH, Wang X, Dip EC, Aguiar-Alves F, Basuino L, Marbach H, Mai TT, Sarda MN, Kajikawa O, Matute-Bello G, Tkaczyk C, Rasigade JP, Sellman BR, Chambers HF, Lina G. IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Volume 8 of Issue 357. Science translational medicine 2016. PMID: 27655850


  77. Baxi SM, Clemenzi-Allen A, Gahbauer A, Deck D, Imp B, Vittinghoff E, Chambers HF, Doernberg S. Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia. Antimicrobial agents and chemotherapy 2016. PMID: 27324762


  78. Pollett S, Baxi SM, Rutherford GW, Doernberg SB, Bacchetti P, Chambers HF. Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center. Antimicrobial agents and chemotherapy 2016. PMID: 27216053


  79. Chambers HF, Basuino L, Hamilton SM, Choo EJ, Moise P. Daptomycin-ß-Lactam Combinations in a Rabbit Model of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Endocarditis. Antimicrobial agents and chemotherapy 2016. PMID: 27090173


  80. Chan LC, Gilbert A, Basuino L, da Costa TM, Hamilton SM, Dos Santos KR, Chambers HF, Chatterjee SS. PBP 4 Mediates High-Level Resistance to New-Generation Cephalosporins in Staphylococcus aureus. Antimicrobial agents and chemotherapy 2016. PMID: 27067335


  81. Greninger AL, Chatterjee SS, Chan LC, Hamilton SM, Chambers HF, Chiu CY. Whole-Genome Sequencing of Methicillin-Resistant Staphylococcus aureus Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-mecA Mechanisms of Resistance. Volume 11 of Issue 2. PloS one 2016. PMID: 26890675


  82. Miller LG, Daum RS, Chambers HF. Antibacterial Treatment for Uncomplicated Skin Infections. 2015. PMID: 26083210


  83. Chan LC, Basuino L, Dip EC, Chambers HF. Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. Antimicrobial agents and chemotherapy 2015. PMID: 25801564


  84. Miller LG, Daum RS, Creech CB, Young D, Downing MD, Eells SJ, Pettibone S, Hoagland RJ, Chambers HF. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. The New England journal of medicine 2015. PMID: 25785967


  85. Chan LC, Basuino L, Diep B, Hamilton S, Chatterjee SS, Chambers HF. Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus. Volume 59 of Issue 5. Antimicrobial agents and chemotherapy 2015. PMID: 25753637


  86. Chambers HF. Probability of eradication using vancomycin alone or in combination for methicillin-resistant Staphylococcus aureus bacteremia. Antimicrobial agents and chemotherapy 2014. PMID: 25392536


  87. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC, Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. 2014. PMID: 24973422


  88. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. 2014. PMID: 24947530


  89. Chambers HF. Pharmacology and the treatment of complicated skin and skin-structure infections. The New England journal of medicine 2014. PMID: 24897088


  90. Date SV, Modrusan Z, Lawrence M, Morisaki JH, Toy K, Shah IM, Kim J, Park S, Xu M, Basuino L, Chan L, Zeitschel D, Chambers HF, Tan MW, Brown EJ, Diep BA, Hazenbos WL. Global gene expression of methicillin-resistant Staphylococcus aureus USA300 during human and mouse infection. Volume 209 of Issue 10. The Journal of infectious diseases 2013. PMID: 24286981


  91. Diep BA, Afasizheva A, Le HN, Kajikawa O, Matute-Bello G, Tkaczyk C, Sellman B, Badiou C, Lina G, Chambers HF. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. Volume 208 of Issue 1. The Journal of infectious diseases 2013. PMID: 23532096


  92. Hsiang MS, Shiau R, Nadle J, Chan L, Lee B, Chambers HF, Pan E. Epidemiologic Similarities in Pediatric Community-Associated Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus in the San Francisco Bay Area. Journal of the Pediatric Infectious Diseases Society 2012. PMID: 23687577


  93. Tattevin P, Schwartz BS, Graber CJ, Volinski J, Bhukhen A, Bhukhen A, Mai TT, Vo NH, Dang DN, Phan TH, Basuino L, Perdreau-Remington F, Chambers HF, Diep BA. Concurrent epidemics of skin and soft tissue infection and bloodstream infection due to community-associated methicillin-resistant Staphylococcus aureus. Volume 55 of Issue 6. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2012. PMID: 22670044


  94. Doernberg SB, Winston LG, Deck DH, Chambers HF. Does doxycycline protect against development of Clostridium difficile infection? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2012. PMID: 22563022


  95. Gardete S, Kim C, Hartmann BM, Mwangi M, Roux CM, Dunman PM, Chambers HF, Tomasz A. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. PLoS pathogens 2012. PMID: 22319446


  96. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011. PMID: 21217178


  97. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011. PMID: 21208910


  98. Banerjee R, Gretes M, Harlem C, Basuino L, Chambers HF. A mecA-negative strain of methicillin-resistant Staphylococcus aureus with high-level ß-lactam resistance contains mutations in three genes. Antimicrobial agents and chemotherapy 2010. PMID: 20805396


  99. Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, Basuino L, Mai TT, Marbach H, Braughton KR, Whitney AR, Gardner DJ, Fan X, Tseng CW, Liu GY, Badiou C, Etienne J, Lina G, Matthay MA, DeLeo FR, Chambers HF. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Volume 107 of Issue 12. Proceedings of the National Academy of Sciences of the United States of America 2010. PMID: 20231457


  100. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated meticillin-resistant Staphylococcus aureus. Lancet (London, England) 2010. PMID: 20206987


  101. Mendes RE, Sader HS, Deshpande LM, Diep BA, Chambers HF, Jones RN. Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid. Volume 48 of Issue 2. Journal of clinical microbiology 2009. PMID: 19940054


  102. Tattevin P, Basuino L, Bauer D, Diep BA, Chambers HF. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 2009. PMID: 19917746


  103. DeLeo FR, Chambers HF. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. The Journal of clinical investigation 2009. PMID: 19729844


  104. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nature reviews. Microbiology 2009. PMID: 19680247


  105. Winston L, Chambers H. Coming home with MRSA. Archives of internal medicine 2009. PMID: 19667300


  106. Schwartz BS, Graber CJ, Diep BA, Basuino L, Perdreau-Remington F, Chambers HF. Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300. Volume 48 of Issue 10. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009. PMID: 19374563


  107. Tattevin P, Basuino L, Chambers HF. Subinhibitory fluoroquinolone exposure selects for reduced beta-lactam susceptibility in methicillin-resistant Staphylococcus aureus and alterations in the SOS-mediated response. Research in microbiology 2009. PMID: 19366630


  108. Li M, Diep BA, Villaruz AE, Braughton KR, Jiang X, DeLeo FR, Chambers HF, Lu Y, Otto M. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Volume 106 of Issue 14. Proceedings of the National Academy of Sciences of the United States of America 2009. PMID: 19293374


  109. Cosgrove SE, Vigliani GA, Fowler VG, Abrutyn E, Corey GR, Levine DP, Rupp ME, Chambers HF, Karchmer AW, Boucher HW. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009. PMID: 19207079


  110. Chambers HF, Basuino L, Diep BA, Steenbergen J, Zhang S, Tattevin P, Alder J. Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis. Antimicrobial agents and chemotherapy 2009. PMID: 19171803


  111. Graber CJ, Jacobson MA, Perdreau-Remington F, Chambers HF, Diep BA. Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic. Volume 49 of Issue 2. Journal of acquired immune deficiency syndromes (1999) 2008. PMID: 18820536


  112. Diep BA, Palazzolo-Ballance AM, Tattevin P, Basuino L, Braughton KR, Whitney AR, Chen L, Kreiswirth BN, Otto M, DeLeo FR, Chambers HF. Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis. Volume 3 of Issue 9. PloS one 2008. PMID: 18787708


  113. Chambers HF, Moellering RC, Kamitsuka P. Clinical decisions. Management of skin and soft-tissue infection. 2008. PMID: 18768953


  114. Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Archives of internal medicine 2008. PMID: 18663172


  115. Liu C, Graber CJ, Karr M, Diep BA, Basuino L, Schwartz BS, Enright MC, O'Hanlon SJ, Thomas JC, Perdreau-Remington F, Gordon S, Gunthorpe H, Jacobs R, Jensen P, Leoung G, Rumack JS, Chambers HF. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. Volume 46 of Issue 11. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008. PMID: 18433335


  116. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008. PMID: 18462092


  117. Diep BA, Stone GG, Basuino L, Graber CJ, Miller A, des Etages SA, Jones A, Palazzolo-Ballance AM, Perdreau-Remington F, Sensabaugh GF, DeLeo FR, Chambers HF. The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus. Volume 197 of Issue 11. The Journal of infectious diseases 2008. PMID: 18700257


  118. Banerjee R, Gretes M, Basuino L, Strynadka N, Chambers HF. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 2008. PMID: 18378703


  119. David MZ, Siegel JD, Chambers HF, Daum RS. Determining whether methicillin-resistant Staphylococcus aureus is associated with health care. JAMA 2008. PMID: 18252879


  120. Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, Chen JH, Lin F, Lin J, Phan TH, Carleton HA, McDougal LK, Tenover FC, Cohen DE, Mayer KH, Sensabaugh GF, Perdreau-Remington F. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Volume 148 of Issue 4. Annals of internal medicine 2008. PMID: 18283202


  121. Rajendran PM, Young D, Maurer T, Chambers H, Perdreau-Remington F, Ro P, Harris H. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrobial agents and chemotherapy 2007. PMID: 17846141


  122. Chambers HF, Hegde SS. Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin? Expert review of anti-infective therapy 2007. PMID: 17547497


  123. Mitchell J, Siboo IR, Takamatsu D, Chambers HF, Sullam PM. Mechanism of cell surface expression of the Streptococcus mitis platelet binding proteins PblA and PblB. Volume 64 of Issue 3. Molecular microbiology 2007. PMID: 17462028


  124. Graber CJ, Wong MK, Carleton HA, Perdreau-Remington F, Haller BL, Chambers HF. Intermediate vancomycin susceptibility in a community-associated MRSA clone. Volume 13 of Issue 3. Emerging infectious diseases 2007. PMID: 17552110


  125. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. The New England journal of medicine 2006. PMID: 16914701


  126. Rutar T, Chambers HF, Crawford JB, Perdreau-Remington F, Zwick OM, Karr M, Diehn JJ, Cockerham KP. Ophthalmic manifestations of infections caused by the USA300 clone of community-associated methicillin-resistant Staphylococcus aureus. Ophthalmology 2006. PMID: 16766029


  127. Seeley EJ, Chambers HF. Diabetic ketoacidosis precipitated by Staphylococcus aureus abscess and bacteremia due to acupuncture: case report and review of the literature. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006. PMID: 16758409


  128. Chambers HF. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006. PMID: 16524424


  129. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC, Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. 2005. PMID: 16231249


  130. Madrigal AG, Basuino L, Chambers HF. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrobial agents and chemotherapy 2005. PMID: 16048918


  131. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC. Imipenem for treatment of tuberculosis in mice and humans. Antimicrobial agents and chemotherapy 2005. PMID: 15980354


  132. Eguia JM, Liu C, Moore M, Wrone EM, Pont J, Gerberding JL, Chambers HF. Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005. PMID: 15889359


  133. Chambers HF. Community-associated MRSA--resistance and virulence converge. 2005. PMID: 15814886


  134. Siboo IR, Chambers HF, Sullam PM. Role of SraP, a Serine-Rich Surface Protein of Staphylococcus aureus, in binding to human platelets. Volume 73 of Issue 4. Infection and immunity 2005. PMID: 15784571


  135. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrobial agents and chemotherapy 2005. PMID: 15728879


  136. Young DM, Harris HW, Charlebois ED, Chambers H, Campbell A, Perdreau-Remington F, Lee C, Mankani M, Mackersie R, Schecter WP. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Archives of surgery (Chicago, Ill. : 1960) 2004. PMID: 15381611


  137. Wilke MS, Hills TL, Zhang HZ, Chambers HF, Strynadka NC. Crystal structures of the Apo and penicillin-acylated forms of the BlaR1 beta-lactam sensor of Staphylococcus aureus. The Journal of biological chemistry 2004. PMID: 15322076


  138. Charlebois ED, Perdreau-Remington F, Kreiswirth B, Bangsberg DR, Ciccarone D, Diep BA, Ng VL, Chansky K, Edlin BR, Edlin B, Chambers HF. Origins of community strains of methicillin-resistant Staphylococcus aureus. Volume 39 of Issue 1. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004. PMID: 15206052


  139. Winston LG, Pang S, Haller BL, Wong M, Chambers HF, Perdreau-Remington F. API 20 strep identification system may incorrectly speciate enterococci with low level resistance to vancomycin. Volume 48 of Issue 4. Diagnostic microbiology and infectious disease 2004. PMID: 15062923


  140. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. 2004. PMID: 15034832


  141. Katayama Y, Zhang HZ, Chambers HF. PBP 2a mutations producing very-high-level resistance to beta-lactams. Antimicrobial agents and chemotherapy 2004. PMID: 14742194


  142. Eguia JM, Chambers HF. Community-acquired Methicillin-resistant Staphylococcus aureus: Epidemiology and Potential Virulence Factors. Current infectious disease reports 2003. PMID: 14642185


  143. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrobial agents and chemotherapy 2003. PMID: 14506006


  144. Katayama Y, Zhang HZ, Hong D, Chambers HF. Jumping the barrier to beta-lactam resistance in Staphylococcus aureus. Journal of bacteriology 2003. PMID: 12949098


  145. Chambers HF. Solving staphylococcal resistance to beta-lactams. Trends in microbiology 2003. PMID: 12706985


  146. Moore MR, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrobial agents and chemotherapy 2003. PMID: 12654656


  147. Eguia JM, Chambers HF. Methicillin-resistant staphylococci and their treatment in the intensive care unit. Seminars in respiratory and critical care medicine 2003. PMID: 16088523


  148. Katayama Y, Zhang HZ, Chambers HF. Effect of disruption of Staphylococcus aureus PBP4 gene on resistance to beta-lactam antibiotics. Microbial drug resistance (Larchmont, N.Y.) 2003. PMID: 15000739


  149. Winston LG, Bangsberg DR, Chambers HF, Felt SC, Rosen JI, Charlebois ED, Wong M, Steele L, Gerberding JL, Perdreau-Remington F. Epidemiology of vancomycin-resistant Enterococcus faecium under a selective isolation policy at an urban county hospital. American journal of infection control 2002. PMID: 12410216


  150. Charlebois ED, Bangsberg DR, Moss NJ, Moore MR, Moss AR, Chambers HF, Perdreau-Remington F. Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002. PMID: 11797167


  151. Kanaya AM, Glidden DV, Chambers HF. Identifying pulmonary tuberculosis in patients with negative sputum smear results. Chest 2001. PMID: 11502628


  152. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerging infectious diseases 2001. PMID: 11294701


  153. Chambers HF. Methicillin-resistant Staphylococcus aureus. Mechanisms of resistance and implications for treatment. Postgraduate medicine 2001. PMID: 19667557


  154. Chambers HF, Xiang Q, Chow LL, Hackbarth C. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus. Antimicrobial agents and chemotherapy 1999. PMID: 10543757


  155. Martin JN, Perdreau-Remington F, Kartalija M, Pasi OG, Webb M, Gerberding JL, Chambers HF, Täuber MG, Lee BL. A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. 1999. PMID: 10438389


  156. Kim YS, Liu Q, Chow LL, Chambers HF, Täuber MG. Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 1998. PMID: 9835540


  157. Sheppard DC, Chambers HF. Suppurative parotitis. The Western journal of medicine 1998. PMID: 9735697


  158. Chambers HF, Kocagöz T, Sipit T, Turner J, Hopewell PC. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998. PMID: 9564467


  159. Hackbarth CJ, Unsal I, Chambers HF. Cloning and sequence analysis of a class A beta-lactamase from Mycobacterium tuberculosis H37Ra. Antimicrobial agents and chemotherapy 1997. PMID: 9145897


  160. Sweet-Cordero EA, Chambers HF, Cicero-Sabido R, Santos-Preciado JI. Burden of Mycobacterium tuberculosis in sputum samples can be reliably determined using a quantitative, non-radioactive polymerase chain reaction assay. Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 1996. PMID: 9039441


  161. Kocagöz T, Hackbarth CJ, Unsal I, Rosenberg EY, Nikaido H, Chambers HF. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrobial agents and chemotherapy 1996. PMID: 8843279


  162. Frank U, Chambers HF. Treatment of Staphylococcus aureus catheter-related infection and infective endocarditis with granulocyte colony-stimulating factor in the experimental rabbit model. Antimicrobial agents and chemotherapy 1996. PMID: 8723492


  163. Lee BL, Täuber MG, Sadler B, Goldstein D, Chambers HF. Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Clinical pharmacology and therapeutics 1996. PMID: 8549029


  164. Chambers HF, Moreau D, Yajko D, Miick C, Wagner C, Hackbarth C, Kocagöz S, Rosenberg E, Hadley WK, Nikaido H. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrobial agents and chemotherapy 1995. PMID: 8592990


  165. Yajko DM, Wagner C, Tevere VJ, Kocagöz T, Hadley WK, Chambers HF. Quantitative culture of Mycobacterium tuberculosis from clinical sputum specimens and dilution endpoint of its detection by the Amplicor PCR assay. Journal of clinical microbiology 1995. PMID: 7665679


  166. Chambers HF, Kartalija M, Sande M. Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits. The Journal of infectious diseases 1995. PMID: 7706817


  167. Chambers HF. In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a. Antimicrobial agents and chemotherapy 1995. PMID: 7726516


  168. Hackbarth CJ, Kocagoz T, Kocagoz S, Chambers HF. Point mutations in Staphylococcus aureus PBP 2 gene affect penicillin-binding kinetics and are associated with resistance. Antimicrobial agents and chemotherapy 1995. PMID: 7695289


  169. Hackbarth CJ, Miick C, Chambers HF. Altered production of penicillin-binding protein 2a can affect phenotypic expression of methicillin resistance in Staphylococcus aureus. Antimicrobial agents and chemotherapy 1994. PMID: 7872749


  170. Chambers HF, Fournier MA. Efficacy of cefoperazone in combination with sulbactam in experimental Staphylococcus aureus endocarditis in rabbits. The Journal of antimicrobial chemotherapy 1993. PMID: 8262867


  171. Chambers HF. Detection of methicillin-resistant staphylococci. Infectious disease clinics of North America 1993. PMID: 8345177


  172. Hackbarth CJ, Chambers HF. blaI and blaR1 regulate beta-lactamase and PBP 2a production in methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 1993. PMID: 8517704


  173. Chambers HF. Short-course combination and oral therapies of Staphylococcus aureus endocarditis. Infectious disease clinics of North America 1993. PMID: 8463654


  174. Chambers HF. Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus. The Journal of antimicrobial chemotherapy 1992. PMID: 1399943


  175. Chambers HF, Miick C. Characterization of penicillin-binding protein 2 of Staphylococcus aureus: deacylation reaction and identification of two penicillin-binding peptides. Antimicrobial agents and chemotherapy 1992. PMID: 1622180


  176. Gerberding JL, Miick C, Liu HH, Chambers HF. Comparison of conventional susceptibility tests with direct detection of penicillin-binding protein 2a in borderline oxacillin-resistant strains of Staphylococcus aureus. Antimicrobial agents and chemotherapy 1991. PMID: 1810191


  177. Lee BL, Sachdeva M, Chambers HF. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrobial agents and chemotherapy 1991. PMID: 1667253


  178. Barg N, Chambers H, Kernodle D. Borderline susceptibility to antistaphylococcal penicillins is not conferred exclusively by the hyperproduction of beta-lactamase. Antimicrobial agents and chemotherapy 1991. PMID: 1759816


  179. Chambers HF. Treatment of infection and colonization caused by methicillin-resistant Staphylococcus aureus. Infection control and hospital epidemiology 1991. PMID: 1847961


  180. Chambers HF, Sachdeva M, Kennedy S. Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. The Journal of infectious diseases 1990. PMID: 2387996


  181. Stratton CW, Gelfand MS, Gerberding JL, Chambers HF. Characterization of mechanisms of resistance to beta-lactam antibiotics in methicillin-resistant strains of Staphylococcus saprophyticus. Antimicrobial agents and chemotherapy 1990. PMID: 2285290


  182. Chambers HF, Sachdeva M. Binding of beta-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus. The Journal of infectious diseases 1990. PMID: 2345297


  183. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrobial agents and chemotherapy 1990. PMID: 2393284


  184. Chambers HF, Kennedy S. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrobial agents and chemotherapy 1990. PMID: 2140496


  185. Dworkin RJ, Lee BL, Sande MA, Chambers HF. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet (London, England) 1989. PMID: 2572799


  186. Padula A, Chambers HF. Evaluation of cilofungin (LY121019) for treatment of experimental Candida albicans endocarditis in rabbits. Antimicrobial agents and chemotherapy 1989. PMID: 2686548


  187. Kennedy S, Chambers HF. Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits. Antimicrobial agents and chemotherapy 1989. PMID: 2554799


  188. Hackbarth CJ, Chambers HF. Methicillin-resistant staphylococci: detection methods and treatment of infections. Antimicrobial agents and chemotherapy 1989. PMID: 2675760


  189. Hackbarth CJ, Chambers HF. Methicillin-resistant staphylococci: genetics and mechanisms of resistance. Antimicrobial agents and chemotherapy 1989. PMID: 2675759


  190. Chambers HF, Archer G, Matsuhashi M. Low-level methicillin resistance in strains of Staphylococcus aureus. Antimicrobial agents and chemotherapy 1989. PMID: 2729937


  191. Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Annals of internal medicine 1988. PMID: 3421575


  192. Jacobson MA, Gellermann H, Chambers H. Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS-related complex. The American journal of medicine 1988. PMID: 3400693


  193. Chambers HF. Methicillin-resistant staphylococci. Clinical microbiology reviews 1988. PMID: 3069195


  194. Chambers HF. Coagulase-negative staphylococci resistant to beta-lactam antibiotics in vivo produce penicillin-binding protein 2a. Antimicrobial agents and chemotherapy 1987. PMID: 3439802


  195. Chambers HF, Hackbarth CJ. Effect of NaCl and nafcillin on penicillin-binding protein 2a and heterogeneous expression of methicillin resistance in Staphylococcus aureus. Antimicrobial agents and chemotherapy 1987. PMID: 3439805


  196. Sachdeva M, Hackbarth C, Stella FB, Chambers HF. Comparative activity of CGP 31608, nafcillin, cefamandole, imipenem, and vancomycin against methicillin-susceptible and methicillin-resistant staphylococci. Antimicrobial agents and chemotherapy 1987. PMID: 3481245


  197. Chambers HF, Miller MH. Emergence of resistance to cephalothin and gentamicin during combination therapy for methicillin-resistant Staphylococcus aureus endocarditis in rabbits. The Journal of infectious diseases 1987. PMID: 3643249


  198. Carpenter TC, Hackbarth CJ, Chambers HF, Sande MA. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus. Antimicrobial agents and chemotherapy 1986. PMID: 3640590


  199. Hackbarth CJ, Chambers HF, Sande MA. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrobial agents and chemotherapy 1986. PMID: 3707110


  200. Chambers HF, Hartman BJ, Tomasz A. Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus exposed to nafcillin. The Journal of clinical investigation 1985. PMID: 4019783


  201. Sullam PM, Täuber MG, Hackbarth CJ, Chambers HF, Scott KG, Sande MA. Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus. Antimicrobial agents and chemotherapy 1985. PMID: 3860185


  202. Chambers HF, Mills J, Drake TA, Sande MA. Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus. Reviews of infectious diseases 1984. PMID: 6522927


  203. Chambers HF, Sande MA. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 1984. PMID: 6236747


  204. Chambers HF, Hackbarth CJ, Drake TA, Rusnak MG, Sande MA. Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to beta-lactam antibiotics in vivo and in vitro. The Journal of infectious diseases 1984. PMID: 6564133


  205. Chambers HF, Korzeniowski OM, Sande MA. Staphylococcus aureus endocarditis: clinical manifestations in addicts and nonaddicts. Medicine 1983. PMID: 6843356